Patent application number | Description | Published |
20090246862 | BIOLUMINOGENIC ASSAY SYSTEM FOR MEASURING BETA-LACTAMASE ACTIVITY - A bioluminogenic assay system including: providing a bioluminogenic substrate incorporating a beta-lactam antibiotic, a bioluminescence initiating compound, and a chemical linkage joining the beta-lactam antibiotic to the bioluminescence initiating compound; exposing the bioluminogenic substrate to a beta-lactamase enzyme that catalyzes the release of the bioluminescence initiating compound from the bioluminogenic substrate; co-exposing the bioluminogenic substrate to a bioluminescence indicator reaction that employs the bioluminescence initiating compound as a substrate; and detecting a light from the bioluminescence indicator reaction as a measure of the activity of the beta-lactamase enzyme. | 10-01-2009 |
20100035290 | ENZYME DETECTION SYSTEM WITH CAGED SUBSTRATES - An enzyme detection method includes forming a caged substrate; releasing an uncaged substrate by cleaving a caging molecules from the caged substrate; and emitting a light emission from a Bioluminescence Resonance Energy Transfer luminescent nanocrystal conjugate reacting with the uncaged substrate. | 02-11-2010 |
20100047172 | Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics - Provided herein are imaging methods for detecting, diagnosing and imaging pathogenic bacteria or a pathophysiological condition associated therewith using fluorescent, luminescent or colorimetric detection agents, e.g., fluorogenic substrates for bacterial enzymes, caged luciferins and fluorescent proteins, luciferases and enzymes expressed by recombinant bacteria. Signals emitted by the fluorescent, luminescent or colorimetric detection agents in the presence of the bacteria are compared to controls to detect and locate the pathogenic bacteria. Also provided is a method for screening therapeutic agents to treat the pathophysiological conditions by measuring fluorescence or luminescence emitted from the detection agents in the presence and absence of the potential therapeutic agent. In addition, a method for detecting a pathogenic bacteria via PET or SPECT imaging using a positron-emitting or gamma-emitting substrate for a beta-lactamase or other enzyme or protein of the pathogenic bacteria. Further provided are the fluorogenic substrates CNIR-7 or CNIR7-TAT or the radiolabeled substrates. | 02-25-2010 |
20100055725 | SYSTEM FOR ASSAYS OF AMINOTRANSFERASE - An assay system ( | 03-04-2010 |
20100068741 | ASSAY SYSTEM FOR ADENOSINE TRIPHOSPHATE AND CREATINE KINASE - An assay method includes providing a luminescent nanocrystal; combining a solution having an adenosine triphosphate molecule; and displaying a light emission by the luminescent nanocrystal and the solution combined. | 03-18-2010 |
20110020240 | Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics - Provided herein are imaging methods for detecting, diagnosing and imaging pathogenic bacteria or a pathophysiological condition associated therewith using fluorogenic substrates for bacterial enzymes. Fluorescent, luminescent or colorimetric signals emitted by substrates or enzyme products in the presence of the bacteria are compared to controls to detect and locate the pathogenic bacteria. Provided is a method for screening therapeutic agents to treat the pathophysiological conditions by measuring a signal emitted from the fluorogenic substrates or products in the presence and absence of the potential therapeutic agent. In addition, a diagnostic method for detecting a mycobacterial infection in a subject by contacting biological samples with a fluorogenic substrate and imaging for signals emitted from a mycobacterial beta-lactamase product. Provided are fluorogenic substrates CC1, CC2, CHPQ, CR2, CNIR1, CNIR2, CNIR3, CNIR4, CNIR5, CNIR5-QSY22, CNIR7, CNIR9, CNIR10, CNIR-TAT, CDC-1, CDC-2, CDC-3, CDC-4, CDC-5, XHX2-81, XHX2-91, XHX3-26, or XHX3-32 or a derivative thereof. | 01-27-2011 |
20110200529 | ACTIVATABLE BIOLUMINESCENT PROBE SYSTEM AND METHOD OF USE THEREOF - A method of use of an activatable bioluminescent probe system includes: providing a bioluminescent protein and a quencher in a reaction environment; modifying a ligand between the quencher and the bioluminescent protein using a ligand interacting molecule; adding a bioluminescence initiating molecule to the reaction environment; and measuring light originating from the interaction between the bioluminescent protein and the bioluminescence initiating molecule. | 08-18-2011 |
20110201781 | CYSTEINE LABELING SYSTEM AND METHOD OF USE THEREOF - A method of use of a cysteine labeling system includes: providing a 2-cyano benzothial core with a covalently-linked biomolecule X in a reaction environment; and reacting the 2-cyano benzothial core to an N-terminal cystenine. | 08-18-2011 |
20110278554 | Hybrid quantum dot/protein nanostructure, methods of making, and methods of use thereof - Embodiments of the present disclosure include hybrid quantum dot/protein nanostructure, hybrid quantum dot/protein nanostructure systems, methods of using hybrid quantum dot/protein nanostructures, and the like. | 11-17-2011 |
20130164221 | USE OF BACTERIAL BETA-LACTAMASE FOR IN VITRO DIAGNOSTICS AND IN VIVO IMAGING, DIAGNOSTICS AND THERAPEUTICS - Provided herein are methods for detecting, quantifying, differentiating, diagnosing and imaging pathogenic bacteria or condition associated therewith using substrates for bacterial enzymes. Fluorescent, luminescent or colorimetric signals emitted by substrates or enzyme products in the presence of the bacteria are compared to controls to detect and locate the pathogenic bacteria. Provided is a method for screening therapeutic agents to treat the pathophysiological conditions by measuring a signal emitted from the substrates or products in the presence and absence of the potential therapeutic agent and a diagnostic method for detecting a mycobacterial infection in a subject by contacting biological samples with a substrate and imaging for signals emitted from a mycobacterial beta-lactamase product. Also provided are fluorogenic substrates or substrates comprising a colored dye or a chemical reagent effective to induce a color or pH change. | 06-27-2013 |
20130272966 | RET2IR CONJUGATES, RET2IR CONJUGATE SYSTEMS AND METHODS OF USE THEREOF - Embodiments of the present disclosure include conjugate systems, methods of using conjugate systems, RET | 10-17-2013 |
20140004049 | NANOPROBES FOR SENSING OF REACTIVE OXYGEN AND REACTIVE NITROGEN SPECIES | 01-02-2014 |
20140127712 | USE OF BACTERIAL BETA-LACTAMASE FOR IN VITRO DIAGNOSTICS AND IN VIVO IMAGING, DIAGNOSTICS AND THERAPEUTICS - Provided herein are assays and in vitro methods to determine susceptibility to a drug effective against a pathogenic bacteria, for example, a pathogenic Mycobacteria, that has a beta-lactamase activity. An excitation wavelength is delivered to a biological sample obtained from a subject having an infection from the pathogenic bacteria in the presence of a beta-lactamase substrate. The intensity of a signal, such as a fluorescent, luminescent or colorimetric signal, at an emission wavelength of a product of the beta-lactamase on the subject is correlated to drug susceptibility. Also provided is an assay system for monitoring drug susceptibility of a pathogenic bacteria comprising color-producing substrates for a beta-lactamase of the pathogenic bacteria, an assay device for visibly detecting a product of the beta-lactamase on the substrate thereof and a reader configured to quantify the visibly detected product. | 05-08-2014 |
20150031996 | SEMICONDUCTING POLYMER NANOPARTICLES AS PHOTOACOUSTIC MOLECULAR IMAGING PROBES - Provided are nanoparticles comprising an organic photovoltaic semiconductor polymer and a phospholipid, the semiconductor polymer being near-infra red absorbing and generating a detectable photoacoustic signal and a fluorescent emission when irradiated by an incident activation energy. Also provided are methods of molecular imaging, comprising delivering to a subject a plurality of said nanoparticles, irradiating the subject with a first incident energy to generate a first photoacoustic signal, irradiating the subject with a second incident energy to generate a second photoacoustic signal, determining a ratio of the intensities of the two photoacoustic signals, comparing this first ratio with a second ratio determined from the nanoparticles before delivery to the subject, whereby a difference in said first and second ratios indicates ROS degradation of the nanoparticles in the subject; and generating a ratiometric image indicating the difference in said first and second ratios relative to an image of the subject. | 01-29-2015 |
20150056137 | CASPASE-TRIGGERED NANO-AGGREGATION PROBES AND METHODS OF USE - Provided is an activatable probe that undergoes intramolecular cyclization and subsequent aggregation in apoptotic tumor cells upon peptidase-initiated, and most advantageously caspase-3, activation. These caspase-sensitive nano-aggregation probes (C-SNAFs) are generally biocompatible, possess NIR spectral properties or may serve as PET or MRI imaging agents, and have a mechanism of target-mediated nanostructure self-assembly amenable to in vivo use. The probes encompass biocompatible condensation chemistry products that comprise D-cysteine and 2-cyano-6-hydroxyquinoline (CHQ) moieties linked to an amino-luciferin scaffold, and which can be activated by a two-step reaction requiring caspase-3/7-mediated cleavage of an aspartate-glutamate-valine-aspartate (L-DEVD) capping peptide and the free intracellular thiol-mediated reduction of the disulfide bond. | 02-26-2015 |